Immunogenicity and Safety Study of a Third Vaccination With FSME-IMMUN 0.5 mL in Subjects Previously Vaccinated According to a Rapid Immunization Schedule (Follow-up to Study 225)

NCT00163540 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

INDUSTRY

Sponsor class

Conditions

Encephalitis, Tick-borne

Interventions

BIOLOGICAL: Formaldehyde inactivated, sucrose gradient purified TBE virus antigen, strain Neudörfl

Sponsor

Pfizer